# reload+after+2024-01-21 16:45:02.619967
address1§Generaal De Wittelaan L11 A3
city§Mechelen
zip§2800
country§Belgium
phone§32 1 534 29 00
fax§32 1 534 29 01
website§https://www.glpg.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of?various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also comprise GLPG3667 that has completed Phase 1b trial; and GLPG5101 and GLPG5201, CD19 CAR-T product candidate manufactures at point-of-care, that is in Phase I/II in relapsed/refractory non-Hodgkin lymphoma and chronic lymphocytic leukemia. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.
fullTimeEmployees§1338
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Paulus A. Stoffels M.D., Ph.D.', 'age': 61, 'title': 'CEO, Chairman, Interim Head of R&D', 'yearBorn': 1962, 'fiscalYear': 2022, 'totalPay': 986040, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Michele  Manto M.B.A.', 'age': 50, 'title': 'Chief Commercial Officer', 'yearBorn': 1973, 'fiscalYear': 2022, 'totalPay': 636615, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Thad  Huston', 'age': 53, 'title': 'CFO & COO', 'yearBorn': 1970, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Sofie  Van Gijsel', 'title': 'Head of Investor Relations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Valeria  Cnossen', 'title': 'General Counsel', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Marieke  Vermeersch', 'title': 'Head of Corporate Communication', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Annelies  Missotten', 'title': 'Chief Human Resources Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Ellen Van Der Aar', 'title': 'Head of Development', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Philippe  Alen', 'title': 'Senior VP & Head of Business Development', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Dirk  De Naeyer', 'title': 'Head of Development Operations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§6
boardRisk§4
compensationRisk§10
shareHolderRightsRisk§1
overallRisk§7
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§0.071
priceToSalesTrailing12Months§5.020204
currency§USD
dateShortInterest§1702598400
forwardEps§-2.78
pegRatio§-0.87
exchange§NMS
quoteType§EQUITY
shortName§Galapagos NV
longName§Galapagos NV
firstTradeDateEpochUtc§1330353000
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§8ade642a-64d7-348a-ab37-8edc49ae1242
gmtOffSetMilliseconds§-18000000
targetHighPrice§62.2
targetLowPrice§38.13
targetMeanPrice§45.04
targetMedianPrice§40.62
recommendationMean§2.7
recommendationKey§hold
numberOfAnalystOpinions§5
quickRatio§8.749
earningsGrowth§0.19
grossMargins§0.11598
ebitdaMargins§-0.25617
trailingPegRatio§None
